Pharma

Your Article Summary

See Latest Articles

Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban
BayNews International, 08/31/09

ROCKET AF study compares rivaroxaban to warfarin in the prevention of stroke and non–CNS systemic embolism in patients with Atrial Fibrillation / Bayer Schering Pharma supports Thrombosis Research Institute’s launch of GARFIELD – a global patient Registry to evaluate 'real life' outcomes in the prevention of stroke in patients with Atrial Fibrillation / Fast Track designation for rivaroxaban development program in the secondary prevention of cardiovascular events in patients with Acute Coronary Syndrome recognizes high unmet medical need.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

 See all of Drug Trials